CHICAGO, IL—In a population of patients with paroxysmal atrial fibrillation (AF) deemed to be at low risk of progression, first-line cryoballoon ablation reduced the likelihood of developing ...
Daiichi Sankyo and AstraZeneca’s ENHERTU plus pertuzumab showed a median progression-free survival greater than three years First trial in more than a decade to demonstrate an improvement in outcomes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results